Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T53562
(Former ID: TTDI00081)
|
|||||
Target Name |
X-ray repair cross-complementing 5 (Ku80)
|
|||||
Synonyms |
X-ray repair cross-complementing protein 5; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining); Thyroid-lupus autoantigen; TLAA; Nuclear factor IV; Lupus Ku autoantigen protein p86; Ku86; G22P2; DNA repair protein XRCC5; CTCBF; CTC85; CTC box-binding factor 85 kDa subunit; ATP-dependent DNA helicase II 80 kDa subunit; ATP-dependent DNA helicase 2 subunit 2; 86 kDa subunit of Ku antigen
Click to Show/Hide
|
|||||
Gene Name |
XRCC5
|
|||||
Target Type |
Literature-reported target
|
[1] | ||||
Function |
Has a role in chromosome translocation. The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner. It works in the 3'-5' direction. Binding to DNA may be mediated by XRCC6. Involved in DNA non-homologous end joining (NHEJ) required for double-strand break repair and V(D)J recombination. The XRCC5/6 dimer acts as regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold. The XRCC5/6 dimer is probably involved in stabilizing broken DNA ends and bringing them together. The assembly of the DNA-PK complex to DNA ends is required for the NHEJ ligation step. In association with NAA15, the XRCC5/6 dimer binds to the osteocalcin promoter and activates osteocalcin expression. The XRCC5/6 dimer probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks. XRCC5 probably acts as the catalytic subunit of 5'-dRP activity, and allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined. The XRCC5/6 dimer together with APEX1 acts as a negative regulator of transcription. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway. Single-stranded DNA-dependent ATP-dependent helicase.
Click to Show/Hide
|
|||||
BioChemical Class |
Acid anhydride hydrolase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.6.4.-
|
|||||
Sequence |
MVRSGNKAAVVLCMDVGFTMSNSIPGIESPFEQAKKVITMFVQRQVFAENKDEIALVLFG
TDGTDNPLSGGDQYQNITVHRHLMLPDFDLLEDIESKIQPGSQQADFLDALIVSMDVIQH ETIGKKFEKRHIEIFTDLSSRFSKSQLDIIIHSLKKCDISLQFFLPFSLGKEDGSGDRGD GPFRLGGHGPSFPLKGITEQQKEGLEIVKMVMISLEGEDGLDEIYSFSESLRKLCVFKKI ERHSIHWPCRLTIGSNLSIRIAAYKSILQERVKKTWTVVDAKTLKKEDIQKETVYCLNDD DETEVLKEDIIQGFRYGSDIVPFSKVDEEQMKYKSEGKCFSVLGFCKSSQVQRRFFMGNQ VLKVFAARDDEAAAVALSSLIHALDDLDMVAIVRYAYDKRANPQVGVAFPHIKHNYECLV YVQLPFMEDLRQYMFSSLKNSKKYAPTEAQLNAVDALIDSMSLAKKDEKTDTLEDLFPTT KIPNPRFQRLFQCLLHRALHPREPLPPIQQHIWNMLNPPAEVTTKSQIPLSKIKTLFPLI EAKKKDQVTAQEIFQDNHEDGPTAKKLKTEQGGAHFSVSSLAEGSVTSVGSVNPAENFRV LVKQKKASFEEASNQLINHIEQFLDTNETPYFMKSIDCIRAFREEAIKFSEEQRFNNFLK ALQEKVEIKQLNHFWEIVVQDGITLITKEEASGSSVTAEEAKKFLAPKDKPSGDTAAVFE EGGDVDDLLDMI Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Myo-inositol hexaphosphate | Ligand Info | |||||
Structure Description | DNA-PK complex of DNA end processing | PDB:7SGL | ||||
Method | Electron microscopy | Resolution | 3.00 Å | Mutation | No | [2] |
PDB Sequence |
NKAAVVLCMD
15 VGFTMSNSIP25 GIESPFEQAK35 KVITMFVQRQ45 VFAENKDEIA55 LVLFGTDGTD 65 NPLSGGDQYQ75 NITVHRHLML85 PDFDLLEDIE95 SKIQPGSQQA105 DFLDALIVSM 115 DVIQHETIGK125 KFEKRHIEIF135 TDLSSRFSKS145 QLDIIIHSLK155 KCDISLQFFL 165 PFSLPFRLGG187 HGPSFPLKGI197 TEQQKEGLEI207 VKMVMISLEG217 EDGLDEIYSF 227 SESLRKLCVF237 KKIERHSIHW247 PCRLTIGSNL257 SIRIAAYKSI267 LQERVKKTWT 277 VVDAKTLKKE287 DIQKETVYCL297 NDDDETEVLK307 EDIIQGFRYG317 SDIVPFSKVD 327 EEQMKYKSEG337 KCFSVLGFCK347 SSQVQRRFFM357 GNQVLKVFAA367 RDDEAAAVAL 377 SSLIHALDDL387 DMVAIVRYAY397 DKRANPQVGV407 AFPHIKHNYE417 CLVYVQLPFM 427 EDLRQYMFSS437 LKNSKKYAPT447 EAQLNAVDAL457 IDSMSLAKKD467 EKTDTLEDLF 477 PTTKIPNPRF487 QRLFQCLLHR497 ALHPREPLPP507 IQQHIWNMLN517 PPAEVTTKSQ 527 IPLSKIKTLF537 PLIEAKKKDQ547 VTAQEIFQAE596 NFRVLVKQKK606 ASFEEASNQL 616 INHIEQFLDT626 NETPYFMKSI636 DCIRAFREEA646 IKFSEEQRFN656 NFLKALQEKV 666 EIKQLNHFWE676 IVDVDDLLDM731 I
|
|||||
|
||||||
Click to View More Binding Site Information of This Target and Ligand Pair | ||||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
Biological Network Descriptors
|
There is no similarity protein (E value < 0.005) for this target
|
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Non-homologous end-joining | hsa03450 | Affiliated Target |
|
Class: Genetic Information Processing => Replication and repair | Pathway Hierarchy |
Degree | 31 | Degree centrality | 3.33E-03 | Betweenness centrality | 3.84E-04 |
---|---|---|---|---|---|
Closeness centrality | 2.37E-01 | Radiality | 1.42E+01 | Clustering coefficient | 3.53E-01 |
Neighborhood connectivity | 3.63E+01 | Topological coefficient | 7.88E-02 | Eccentricity | 12 |
Download | Click to Download the Full PPI Network of This Target | ||||
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | XRCC5 cooperates with p300 to promote cyclooxygenase-2 expression and tumor growth in colon cancers. PLoS One. 2017 Oct 19;12(10):e0186900. | |||||
REF 2 | Autophosphorylation transforms DNA-PK from protecting to processing DNA ends. Mol Cell. 2022 Jan 6;82(1):177-189.e4. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.